论文部分内容阅读
目的研究分析阿德福韦酯联合丹参片治疗慢性乙型肝炎(CHB)肝纤维化的临床疗效。方法选取2015年1月至2016年1月我院收治的慢性乙型肝炎纤维化患者92例,随机将患者分为观察组与对照组,每组46例。观察组给予阿德福韦酯联合丹参片进行治疗,对照组单纯采用阿德福韦酯进行治疗。观察并比较两组患者的临床治疗效果情况。结果观察组患者的HBe Ag阴转率、HBe Ag转换率、HBV-DNA阴转率以及脾门厚度与对照组患者相比均具有显著差异,(P<0.05)差异具有统计学意义。结论对于慢性乙型肝炎肝纤维化患者采用阿德福韦酯林和丹参片进行治疗的临床治疗效果确切,安全性高值得在临床上推广应用。
Objective To study the clinical efficacy of adefovir dipivoxil combined with danshen tablet in the treatment of chronic hepatitis B (CHB) liver fibrosis. Methods Totally 92 patients with chronic hepatitis B fibrosis admitted in our hospital from January 2015 to January 2016 were randomly divided into observation group and control group with 46 cases in each group. The observation group was treated with adefovir dipivoxil combined with Danshen tablets and the control group with adefovir dipivoxil alone. Observed and compared the clinical efficacy of the two groups of patients. Results In the observation group, the rates of HBeAg negative conversion, HBeAg conversion, HBV DNA negative rate and splenomegaly were significantly different from those in the control group (P <0.05). Conclusion The clinical treatment of patients with chronic hepatitis B liver fibrosis treated with adefovir dipivoxil and Danshen tablets is effective and safe, worthy of clinical application.